|
1
|
Kessler NJ and Hong J: Whole body
vibration therapy for painful diabetic peripheral neuropathy: a
pilot study. J Bodyw Mov Ther. 17:518–522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kalra B, Kalra S and Bajaj S: Vulvodynia:
An unrecognized diabetic neuropathic syndrome. Indian J Endocrinol
Metab. 17:787–789. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nie F, Wang J, Su D, Shi Y, Chen J, Wang
H, Qin W and Shi L: Abnormal activation of complement C3 in the
spinal dorsal horn is closely associated with progression of
neuropathic pain. Int J Mol Med. 31:1333–1342. 2013.PubMed/NCBI
|
|
4
|
Levin ME, Jin JG, Ji RR, Tong J, Pomonis
JD, Lavery DJ, Miller SW and Chiang LW: Complement activation in
the peripheral nervous system following the spinal nerve ligation
model of neuropathic pain. Pain. 137:182–201. 2008. View Article : Google Scholar
|
|
5
|
Rosoklija GB, Dwork AJ, Younger DS,
Karlikaya G, Latov N and Hays AP: Local activation of the
complement system in endoneurial microvessels of diabetic
neuropathy. Acta Neuropathol. 99:55–62. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lalive PH, Truffert A, Magistris MR,
Landis T and Dosso A: Peripheral autoimmune neuropathy assessed
using corneal in vivo confocal microscopy. Arch Neurol. 66:403–405.
2009.PubMed/NCBI
|
|
7
|
Mamidi S, Cinci M, Hasmann M, Fehring V
and Kirschfink M: Lipoplex mediated silencing of membrane
regulators (CD46, CD55 and CD59) enhances complement-dependent
anti-tumor activity of trastuzumab and pertuzumab. Mol Oncol.
7:580–594. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bani-Ahmad M, El-Amouri IS, Ko CM, Lin F,
Tang-Feldman Y and Oakley OR: The role of decay accelerating factor
in the immunopathogenesis of cytomegalovirus infection. Clin Exp
Immunol. 163:199–206. 2011. View Article : Google Scholar :
|
|
9
|
Galeotti N, Maidecchi A, Mattoli L, Burico
M and Ghelardini C: St. John’s Wort seed and feverfew flower
extracts relieve painful diabetic neuropathy in a rat model of
diabetes. Fitoterapia. 92:23–33. 2014. View Article : Google Scholar
|
|
10
|
Ikeda H, Ikegami M, Kai M, Ohsawa M and
Kamei J: Activation of spinal cannabinoid CB2 receptors inhibits
neuropathic pain in streptozotocin-induced diabetic mice.
Neuroscience. 250:446–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shukla M, Quirion R and Ma W: Reduced
expression of pain mediators and pain sensitivity in amyloid
precursor protein over-expressing CRND8 transgenic mice.
Neuroscience. 250:92–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murakami T, Kanchiku T, Suzuki H, Imajo Y,
Yoshida Y, Nomura H, Cui D, Ishikawa T, Ikeda E and Taguchi T:
Anti-interleukin-6 receptor antibody reduces neuropathic pain
following spinal cord injury in mice. Exp Ther Med. 6:1194–1198.
2013.PubMed/NCBI
|
|
13
|
Bak EJ, Kim J, Jang S, Woo GH, Yoon HG,
Yoo YJ and Cha JH: Gallic acid improves glucose tolerance and
triglyceride concentration in diet-induced obesity mice. Scand J
Clin Lab Invest. 73:607–614. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmitt J, Roderfeld M, Sabrane K, Zhang
P, Tian Y, Mertens JC, Frei P, Stieger B, Weber A, Müllhaupt B,
Roeb E and Geier A: Complement factor C5 deficiency significantly
delays the progression of biliary fibrosis in bile duct-ligated
mice. Biochem Biophys Res Commun. 418:445–450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kato C, Kato A, Adachi K, Fujii E, Isobe
K, Watanabe T, Ito T and Suzuki M: Expression of membrane
complement regulatory proteins Crry and CD55 in normal rats. J
Toxicol Pathol. 26:223–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mishra J, Sahoo PK, Mohanty BR and Das A:
Sequence information, ontogeny and tissue-specific expression of
complement component C3 in Indian major carp, Labeo rohita
(Hamilton). Indian J Exp Biol. 47:672–678. 2009.PubMed/NCBI
|
|
17
|
Zell S, Geis N, Rutz R, Schultz S, Giese T
and Kirschfink M: Down-regulation of CD55 and CD46 expression by
anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes
tumour cells to complement attack. Clin Exp Immunol. 150:576–584.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Loo LS and McNamara JO: Impaired volume
regulation is the mechanism of excitotoxic sensitization to
complement. J Neurosci. 26:10177–10187. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tegla CA, Cudrici C, Rus V, Ito T, Vlaicu
S, Singh A and Rus H: Neuroprotective effects of the complement
terminal pathway during demyelination: implications for
oligodendrocyte survival. J Neuroimmunol. 213:3–11. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tender GC, Li YY and Cui JG: The role of
nerve growth factor in neuropathic pain inhibition produced by
resiniferatoxin treatment in the dorsal root ganglia. Neurosurgery.
73:158–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sundaram B, Singhal K and Sandhir R:
Ameliorating effect of chromium administration on hepatic glucose
metabolism in streptozotocin-induced experimental diabetes.
Biofactors. 38:59–68. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pandey AK, Gupta PP and Lal VK:
Preclinical evaluation of hypoglycemic activity of Ipomoea digitata
tuber in streptozotocin-induced diabetic rats. J Basic Clin Physiol
Pharmacol. 24:35–39. 2013. View Article : Google Scholar
|
|
23
|
Courteix C, Eschalier A and Lavarenne J:
Streptozocin-induced diabetic rats: behavioural evidence for a
model of chronic pain. Pain. 53:81–88. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suehiro K, Funao T, Fujimoto Y, Yamada T,
Mori T and Nishikawa K: Relationship between noradrenaline release
in the locus coeruleus and antiallodynic efficacy of analgesics in
rats with painful diabetic neuropathy. Life Sci. 92:1138–1144.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hsieh CC, Chou HS, Yang HR, Lin F, Bhatt
S, Qin J, Wang L, Fung JJ, Qian S and Lu L: The role of complement
component 3 (C3) in differentiation of myeloid-derived suppressor
cells. Blood. 121:1760–1768. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Berg A, Zelano J, Stephan A, Thams S,
Barres BA, Pekny M, Pekna M and Cullheim S: Reduced removal of
synaptic terminals from axotomized spinal motoneurons in the
absence of complement C3. Exp Neurol. 237:8–17. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mika J, Zychowska M, Popiolek-Barczyk K,
Rojewska E and Przewlocka B: Importance of glial activation in
neuropathic pain. Eur J Pharmacol. 716:106–119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Doehring A, Geisslinger G and Lötsch J:
Epigenetics in pain and analgesia: an imminent research field. Eur
J Pain. 15:11–16. 2011. View Article : Google Scholar
|
|
29
|
Yamamoto H, Fara AF, Dasgupta P and Kemper
C: CD46: the ‘multitasker’ of complement proteins. Int J Biochem
Cell Biol. 45:2808–2820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nevo Y, Ben-Zeev B, Tabib A, Straussberg
R, Anikster Y, Shorer Z, Fattal-Valevski A, Ta-Shma A, Aharoni S,
Rabie M, Zenvirt S, Goldshmidt H, Fellig Y, Shaag A, Mevorach D and
Elpeleg O: CD59 deficiency is associated with chronic hemolysis and
childhood relapsing immune-mediated polyneuropathy. Blood.
121:129–135. 2013. View Article : Google Scholar
|
|
31
|
Margolles-Clark E, Jacques-Silva MC,
Ganesan L, Umland O, Kenyon NS, Ricordi C, Berggren PO and Buchwald
P: Suramin inhibits the CD40-CD154 costimulatory interaction: a
possible mechanism for immunosuppressive effects. Biochem
Pharmacol. 77:1236–1245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nowicki B and Nowicki S: DAF as a
therapeutic target for steroid hormones: implications for
host-pathogen interactions. Adv Exp Med Biol. 735:83–96. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin F, Kaminski HJ, Conti-Fine BM, et al:
Markedly enhanced susceptibility to experimental autoimmune
myasthenia gravis in the absence of decay-accelerating factor
protection. J Clin Invest. 110:1269–1274. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang J, Gerhardinger C and Lorenzi M:
Early complement activation and decreased levels of
glycosylphosphatidylinositol-anchored complement inhibitors in
human and experimental diabetic retinopathy. Diabetes.
51:3499–3504. 2002. View Article : Google Scholar : PubMed/NCBI
|
